Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases
SUZHOU, China, Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $15 million Seed+...
Penetrium Bioscience Unveils Breakthrough Mechanism Solving 137-Year-Old "Seed & Soil" Paradigm, Opening a New Era for Targeted Cancer Therapy
SEOUL, South Korea, April 17, 2026 /PRNewswire/ -- Penetrium Bioscience (KOSDAQ 187660) today announced compelling new scientific evidence demonstrating, for the first time at the cellular level, the underlying mechanism behind the long-standing...
Cardumen Capital Strengthens Global Reach Through Its Taiwan-Based APAC Partner Following NVIDIA's Acquisition of Its Portfolio Company Illumex
Building on the acquisition of Illumex by NVIDIA, the firm validates its Seed-to-Exit thesis and reinforces its mission to bridge Asian capital with world-class DeepTech. TAIPEI, March 10, 2026 /PRNewswire/ -- Cardumen Capital, a leading European...